Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 4, 2000, Pages 432-437

  Simon, Tabassome ^a   Becquemont, Laurent ^b   Mary Krause, Murielle ^b   De Waziers, Isabelle ^b   Beaune, Philippe ^b   Funck Brentano, Christian ^b   Jaillon, Patrice ^b  

^a Saint Antoine University   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUTATHIONE TRANSFERASE; TACRINE;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; DEMOGRAPHY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER TOXICITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034112853     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104944     Document Type: Article

References (27)

1. 1. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-9.
2. 2. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
3. 3. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-8.
4. 4. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
5. 5. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF, et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations: species difference. Drug Metab Dispos 1993;21:874-82.
6. 6. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes. Biochem Pharmacol 1993;46:13-20.
7. 7. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of the fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996:10:156-7.
8. 8. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. Influence of the CYP 1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997:61:619-27.
9. 9. Brockmöller J, Gross D, Kerb R, Drakoulis N, Roots I. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione-S-transferase class Mu gene detected by polymerase chain reaction. Biochem Pharmacol 1992;43:647-50.
10. 10. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GST T1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
11. 11. Warholm M, Rane A, Alexandrie AK, Monaghan G, Rannug A. Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. Pharmacogenetics 1995;5:252-4.
12. 12. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995;39:411-5.
13. 13. Becquemont L, Lecoeur S, Simon T, Beaune P, Funck-Brentano C, Jaillon P. Glutathione S-transferase θ genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics 1997;7:251-3.
14. 14. De Sousa M, Pirmohamed M, Kitteringham N, Woolf T, Park BK. No association between tacrine transaminitis and the glutathione transferase θ genotype in patients with Alzheimer's disease. Pharmacogenetics 1998;8:353-5.
15. 15. Mc Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force in Alzheimer's disease. Neurology 1984;34:939-44.
16. 16. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell Scientific; 1994. p. 469-92.
17. 17. Jourenkova N, Reinikainen M, Bouchardy C, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. Effects of glutathione S-transferase M1 and T1 genotypes on lung cancer risk in smokers. Pharmacogenetics 1997;7:515-8.
18. 18. Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P, Beaune P. Use of heterologously expressed human cytochrome P4501A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8:101-8.
19. 19. El-Zein R, Zwischenberger JB, Wood TG, Abdel-Rahman SZ, Brekelbaum C, Au WW. Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 1997;381:189-200.
20. 20. Lear JT, Smith AG, Heagerty AH, Bowers B, Jones PW, Gilford J, et al. Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma. Carcinogenesis 1997;18:1499-503.
21. 21. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1: environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;11: 901-5.
22. 22. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, et al. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-8.
23. 23. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 1998;7:19-23.
24. 24. Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, et al. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998;77:516-21.
25. 25. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF. Breast cancer and CYP1A1, GST M1, and GST T1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
26. 26. Oude Ophuis MB, Van Lieshout EM, Roelofs HM, Peters WH, Manni JJ. Glutathione-S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998;82:936-43.
27. 27. Trizna Z, De Andrade M, Kyritsis AP, Briggs K, Levin VA, Bruner JM, et al. Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. Cancer Epidemiol Biomarkers Prev 1998;6:553-5.